Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by P.J. Hampton
British Association of Dermatologists guidelines for the management of people with rosacea 2021
GUIDELINES P.J. Hampton Corresponding Author Philip.Hampton@nhs.net guidelines@bad.org.uk orcid.org/0000-0001-6797-2697 Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP U.K Corresponding author Philip Hampton Email: Philip.Hampton@nhs.net guidelines@bad.org.uk Contribution: Conceptualization (lead), Data curation (equal), Supervision (lead), Validation (equal), Writing - original draft (lead), Writing - review & editing (lead) Search for more papers by this author S.
Is Intermittent Brodalumab As Effective As Continuous Dosing?
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel When biological drugs were first introduced for psoriasis, many guidelines suggested cessation of therapy once target outcomes were achieved. Perhaps unsurprisingly, treatment cessation led to rapid relapse in many patients.
New brodalumab psoriasis outcome data suggests that intermittent treatment is as effective as continuous dosing. Is it time to re‐evaluate our treatment regimens?
Commentary P.J. Hampton Corresponding Author hamptonpj@doctors.org.uk orcid.org/https://orcid.org/0000-0001-6797-2697 Department of Dermatology, Newcastle Hospitals NHS Trust, Newcastle, UK Correspondence: Philip Hampton. Email: hamptonpj@doctors.org.uk Contribution: Conceptualization (equal), Supervision (equal), Writing - review & editing (equal) Search for more papers by this author PDF ShareShare Get access to the full version of this article. View access options below.
Expanding Treatment Options for Rosacea
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel Rosacea is a common and troublesome facial dermatosis.
Expanding treatment options for rosacea
Email or Customer ID Please check your email for instructions on resetting your password. If you do not receive an email within 10 minutes, your email address may not be registered, and you may need to create a new Wiley Online Library account.
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Summary Background Real‐world biologic drug survival is an important proxy measure for effectiveness. Predictors of drug survival may help patients with psoriasis choose between biologic therapies. Objectives (i) To assess the relative drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis. (ii) To investigate predictors of biologic drug survival.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with P.J.
Contact P.J., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack